Literature DB >> 31179306

Current anti-copper therapies in management of Wilson disease.

Isabelle Mohr1, Karl Heinz Weiss1.   

Abstract

In Wilson disease (WD) severity of disease can vary widely, depending on time of diagnosis. Early treatment can prevent the development of symptoms in patients. In all patients, lifelong medical treatment is indicated. Currently available medical regimens include the copper chelators for example D-penicillamine (DPA) or trientine (TETA), acting to increase copper excretion and zinc salts (ZS), which reduce copper uptake. In this chapter, we discuss considerations regarding choice of drug and safety limitations.

Entities:  

Keywords:  D-penicillamine (DPA); Trientine (TETA); anti-copper-drugs; zinc

Year:  2019        PMID： 31179306      PMCID： PMC6531644          DOI： 10.21037/atm.2019.02.48

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  53 in total

1.  Effect of foodstuffs on the absorption of zinc sulfate.

Authors:  A Pécoud; P Donzel; J L Schelling
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

Review 2.  A comparative study of in vitro and in vivo interaction of D-penicillamine and triethylenetetramine with copper.

Authors:  B Sarkar; A Sass-Kortsak; R Clarke; S H Laurie; P Wei
Journal:  Proc R Soc Med       Date:  1977

3.  Wilson's disease; new oral therapy.

Authors:  J M WALSHE
Journal:  Lancet       Date:  1956-01-07       Impact factor: 79.321

4.  History of Wilson's disease: 1912 to 2000.

Authors:  John M Walshe
Journal:  Mov Disord       Date:  2006-02       Impact factor: 10.338

5.  Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice.

Authors:  Patrick J Twomey; Adie Viljoen; Ivan M House; Timothy M Reynolds; Anthony S Wierzbicki
Journal:  Clin Chem       Date:  2005-08       Impact factor: 8.327

6.  Wilson's disease in children: 37-year experience and revised King's score for liver transplantation.

Authors:  Anil Dhawan; Rachel M Taylor; Paul Cheeseman; Pamela De Silva; Leah Katsiyiannakis; Giorgina Mieli-Vergani
Journal:  Liver Transpl       Date:  2005-04       Impact factor: 5.799

7.  Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.

Authors:  George J Brewer; Fred Askari; Matthew T Lorincz; Martha Carlson; Michael Schilsky; Karen J Kluin; Peter Hedera; Paolo Moretti; John K Fink; Roberta Tankanow; Robert B Dick; Julia Sitterly
Journal:  Arch Neurol       Date:  2006-04

8.  Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine.

Authors:  Cécile Bécuwe; Stéphane Dalle; Sandra Ronger-Savlé; François Skowron; Brigitte Balme; Jean Kanitakis; Luc Thomas
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

9.  Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.

Authors:  U Merle; M Schaefer; P Ferenci; W Stremmel
Journal:  Gut       Date:  2006-05-18       Impact factor: 23.059

10.  Pros and cons of immunochemical and enzymatic method in the diagnosis of Wilson's disease.

Authors:  J V Gnanou; V G Thykadavil; V Thuppil
Journal:  Indian J Med Sci       Date:  2006-09
View more
  9 in total

1.  Chemical activation of SAT1 corrects diet-induced metabolic syndrome.

Authors:  Federico Pietrocola; Guido Kroemer; Francesca Castoldi; Mervi T Hyvönen; Sylvère Durand; Fanny Aprahamian; Allan Sauvat; Shoaib A Malik; Elisa Elena Baracco; Erika Vacchelli; Paule Opolon; Nicolas Signolle; Déborah Lefevre; Noelie Bossut; Tobias Eisenberg; Christopher Dammbrueck; Tobias Pendl; Margerie Kremer; Sylvie Lachkar; Claudia Einer; Bernhard Michalke; Hans Zischka; Frank Madeo; Tuomo A Keinänen; Maria Chiara Maiuri
Journal:  Cell Death Differ       Date:  2020-05-06       Impact factor: 15.828

Review 2.  Non-invasive radionuclide imaging of trace metal trafficking in health and disease: "PET metallomics".

Authors:  George Firth; Julia E Blower; Joanna J Bartnicka; Aishwarya Mishra; Aidan M Michaels; Alex Rigby; Afnan Darwesh; Fahad Al-Salemee; Philip J Blower
Journal:  RSC Chem Biol       Date:  2022-04-11

Review 3.  Wilson Disease: Update on Pathophysiology and Treatment.

Authors:  Som Dev; Robert L Kruse; James P Hamilton; Svetlana Lutsenko
Journal:  Front Cell Dev Biol       Date:  2022-05-02

4.  Human Embryonic Stem Cell-Derived Wilson's Disease Model for Screening Drug Efficacy.

Authors:  Dongkyu Kim; Su-Bin Kim; Jung Lim Ryu; Heesu Hong; Jin-Hyuk Chang; Tack-Jin Yoo; Xiong Jin; Han-Jin Park; Choongseong Han; Beom Hee Lee; Jin-Ho Choi; Han-Wook Yoo; Jong-Hoon Kim; Dong-Hun Woo
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

Review 5.  The Role of Zinc in the Treatment of Wilson's Disease.

Authors:  Abolfazl Avan; Anna Członkowska; Susan Gaskin; Alberto Granzotto; Stefano L Sensi; Tjaard U Hoogenraad
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

Review 6.  Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders.

Authors:  Mahsa Ghasemzad; Mahdieh Hashemi; Zohre Miri Lavasani; Nikoo Hossein-Khannazer; Haleh Bakhshandeh; Roberto Gramignoli; Hani Keshavarz Alikhani; Mustapha Najimi; Saman Nikeghbalian; Massoud Vosough
Journal:  Bioengineering (Basel)       Date:  2022-08-15

7.  Management of Wilson Disease: The Quest Continues.

Authors:  Gautam Kamila; Biswaroop Chakrabarty
Journal:  Ann Indian Acad Neurol       Date:  2022-09-09       Impact factor: 1.714

8.  Management of Children and Adolescents with Wilson Disease and Neurological Worsening Following D-Penicillamine Therapy: A Single Centre Experience.

Authors:  Madhan Kumar; T P Murugan; Arul P Lionel; Maya M Thomas; Pavithra Mannam; Sangeetha Yoganathan
Journal:  Ann Indian Acad Neurol       Date:  2022-09-09       Impact factor: 1.714

Review 9.  Current Biomedical Use of Copper Chelation Therapy.

Authors:  Silvia Baldari; Giuliana Di Rocco; Gabriele Toietta
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.